Novafix DL is a sterile, single use, dehydrated human amnion chorion membrane
allograft used for safe and effective wound treatment.
INTENDED USE: Novafix DL is intended for use in the management of wounds, including: partial and full thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (e.g., donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds, (e.g., abrasions, lacerations, partial thickness burns, skin tears), and draining wounds. It is applied on a wound after the wound bed is prepared with standard debridement methods. The product will fully resorb and does not have to be removed from the wound bed.
CLAIMED BENEFITS: Novafix DL will fully resorb into the wound and provide a scaffold for cellular infiltration and vascularization. Working as a skin substitute, Novafix DL permits the ingress of cells and soft tissue formation in the defect space or wound bed.
OPTION : Novafix DL is supplied terminally sterile, in a single use package in a variety of sizes. Novafix DL may be fenestrated, and/or reapplied as necessary
Manufacturer: Triad Life Sciences
Information retrieved from manufacturer and/or FDA-approved labels